Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

被引:45
|
作者
Genant, Harry K. [1 ,2 ]
Libanati, Cesar [3 ]
Engelke, Klaus [4 ,5 ]
Zanchetta, Jose R. [6 ]
Hoiseth, Arne [7 ]
Yuen, Chui Kin [8 ]
Stonkus, Sigtas [9 ]
Bolognese, Michael A. [10 ]
Franek, Edward [11 ,12 ]
Fuerst, Thomas [13 ]
Radcliffe, Hoi-Shen [14 ]
McClung, Michael R. [15 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Synarc Inc, San Francisco, CA 94105 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Univ Erlangen Nurnberg, Inst Med Phys, D-91052 Erlangen, Germany
[5] Synarc Inc, Hamburg, Germany
[6] Inst Invest Metab, Buenos Aires, DF, Argentina
[7] Curato Rentgen, Oslo, Norway
[8] SIGMA Canadian Menopause Soc, Vancouver, BC V6H 1E5, Canada
[9] Klaipeda Univ Hosp, LT-92228 Klaipeda, Lithuania
[10] Bethesda Hlth Res, Bethesda, MD 20879 USA
[11] Cent Clin Hosp MSWiA, PL-02507 Warsaw, Poland
[12] Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland
[13] Synarc Inc, Newark, CA 94560 USA
[14] Amgen Ltd, Cambridge CB4 OWD, England
[15] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
关键词
Bone mineral density; Bone mineral content; Denosumab; Hip; Osteoporosis; Quantitative computed tomography; QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; NONINVASIVE ASSESSMENT; FRACTURES; TURNOVER; STRENGTH; ALENDRONATE; PHASE-2; AMG-162;
D O I
10.1016/j.bone.2013.07.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by -1.5% and -2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to <0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. (C) 2013 The Authors. Published by Elsevier Inc All rights reserved.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 50 条
  • [41] Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
    Genant, Harry K.
    Engelke, Klaus
    Bolognese, Michael A.
    Mautalen, Carlos
    Brown, Jacques P.
    Recknor, Chris
    Goemaere, Stefan
    Fuerst, Thomas
    Yang, Yu-Ching
    Grauer, Andreas
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (01) : 181 - 187
  • [42] EFFICACY OF DENOSUMAB FOR CONTROL OF BONE MINERAL DENSITY AND MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A ONE-YEAR EXPERIENCE
    Petranova, Tsvetanka
    Sheytanov, Ivan
    Monov, Simeon
    Rashkov, Rasho
    Kinov, Plamen
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2013, 27 (04) : 3977 - 3981
  • [43] Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
    Silverman, Stuart L.
    Siris, E.
    Belazi, D.
    Recknor, C.
    Papaioannou, A.
    Brown, J. P.
    Gold, D. T.
    Lewiecki, E. M.
    Quinn, G.
    Balasubramanian, A.
    Yue, S.
    Stolshek, B.
    Kendler, D. L.
    ARCHIVES OF OSTEOPOROSIS, 2018, 13 (01)
  • [44] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
    Kendler, David L.
    Roux, Christian
    Benhamou, Claude Laurent
    Brown, Jacques P.
    Lillestol, Michael
    Siddhanti, Suresh
    Man, Hoi-Shen
    Martin, Javier San
    Bone, Henry G.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 72 - 81
  • [45] Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
    Min, Yong-Ki
    ENDOCRINOLOGY AND METABOLISM, 2015, 30 (01) : 19 - 26
  • [46] Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Ouchi
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Takayuki Matsuda
    Makoto Kato
    Eiichi Konishi
    Tetsuya Taguchi
    Journal of Bone and Mineral Metabolism, 2019, 37 : 301 - 306
  • [47] Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis
    Tokutaro Okawa
    Motomi Okawa
    Tatsuya Koike
    Journal of Bone and Mineral Metabolism, 2022, 40 : 960 - 967
  • [48] Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Ouchi, Yoshimi
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Matsuda, Takayuki
    Kato, Makoto
    Konishi, Eiichi
    Taguchi, Tetsuya
    JOURNAL OF BONE AND MINERAL METABOLISM, 2019, 37 (02) : 301 - 306
  • [49] Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
    Ito, Masako
    Sone, Teruki
    Fukunaga, Masao
    JOURNAL OF BONE AND MINERAL METABOLISM, 2010, 28 (03) : 334 - 341
  • [50] Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis
    Lin, T.
    Wang, C.
    Cai, X. -Z.
    Zhao, X.
    Shi, M. -M.
    Ying, Z. -M.
    Yuan, F. -Z.
    Guo, C.
    Yan, S. -G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (04) : 399 - 408